Noradrenalin Versus the Combination of Midodrine and Octreotide in Patients with Hepatorenal Syndrome: Randomized Clinical Trial
Background: Hepatorenal syndrome (HRS) is known as development of acute renal failure in a patient who usually has advanced liver disease. The aim of the present study was to determine the safety and the efficacy of noradrenalin in comparison with midodrine-octreotide in patients with HRS. Methods:...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2012-01-01
|
| Series: | International Journal of Preventive Medicine |
| Subjects: | |
| Online Access: | http://www.ijpvmjournal.net/article.asp?issn=2008-7802;year=2012;volume=3;issue=11;spage=764;epage=769;aulast=Tavakkoli |
| _version_ | 1811305179491860480 |
|---|---|
| author | Hamid Tavakkoli Kambiz Yazdanpanah Marjan Mansourian |
| author_facet | Hamid Tavakkoli Kambiz Yazdanpanah Marjan Mansourian |
| author_sort | Hamid Tavakkoli |
| collection | DOAJ |
| description | Background: Hepatorenal syndrome (HRS) is known as development of acute renal failure in a patient who usually has advanced liver disease. The aim of the present study was to determine the safety and the efficacy of noradrenalin in comparison with midodrine-octreotide in patients with HRS.
Methods: This study was registered to the Iranian Registry of Clinical trials (IRCT). This study was a single-center, randomized, clinical trial that performed in Alzahra hospital, Isfahan, Iran. Since March 2011 to January 2012, twenty-three patients were enrolled in the study. Eligible patients were allocated in 2 groups. In the first group, patients received infusion of NA with the dose of 0.1-0.7 μg/kg/min, and in the other groups, patients received octreotide 100-200 μg subcutaneously 3 times daily and midodrine 5-15 mg orally 3 times daily. In both study groups, patient received albumin infusion in addition to noradrenalin or midodrine-octreotide.
Results: Complete response of HRS was observed in 8 of the 11 patients (73%) treated with noradrenalin and in 9 of the 12 patients (75%) treated with midodrine-octreotide (P > 0.05). HRS recurred after treatment withdrawal in 2 of 11 in NA and 3 of 12 in MO group. That shows no significant difference between 2 groups (P > 0.05).
Conclusion: We deduce that NA has the same efficacy and safety with MO and can induce a complete response in high percentage of the patients. Moreover, we observed no significant differences in the recurrence rate and outcomes after 3 months among the patients in both study groups; this result could support the use of NA in HRS management. The IRCT ID is: IRCT201107217085N1. |
| first_indexed | 2024-04-13T08:21:53Z |
| format | Article |
| id | doaj.art-f55bb43230824eb9be56f8fcdbfb578c |
| institution | Directory Open Access Journal |
| issn | 2008-7802 2008-8213 |
| language | English |
| last_indexed | 2024-04-13T08:21:53Z |
| publishDate | 2012-01-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | International Journal of Preventive Medicine |
| spelling | doaj.art-f55bb43230824eb9be56f8fcdbfb578c2022-12-22T02:54:38ZengWolters Kluwer Medknow PublicationsInternational Journal of Preventive Medicine2008-78022008-82132012-01-01311764769Noradrenalin Versus the Combination of Midodrine and Octreotide in Patients with Hepatorenal Syndrome: Randomized Clinical TrialHamid TavakkoliKambiz YazdanpanahMarjan MansourianBackground: Hepatorenal syndrome (HRS) is known as development of acute renal failure in a patient who usually has advanced liver disease. The aim of the present study was to determine the safety and the efficacy of noradrenalin in comparison with midodrine-octreotide in patients with HRS. Methods: This study was registered to the Iranian Registry of Clinical trials (IRCT). This study was a single-center, randomized, clinical trial that performed in Alzahra hospital, Isfahan, Iran. Since March 2011 to January 2012, twenty-three patients were enrolled in the study. Eligible patients were allocated in 2 groups. In the first group, patients received infusion of NA with the dose of 0.1-0.7 μg/kg/min, and in the other groups, patients received octreotide 100-200 μg subcutaneously 3 times daily and midodrine 5-15 mg orally 3 times daily. In both study groups, patient received albumin infusion in addition to noradrenalin or midodrine-octreotide. Results: Complete response of HRS was observed in 8 of the 11 patients (73%) treated with noradrenalin and in 9 of the 12 patients (75%) treated with midodrine-octreotide (P > 0.05). HRS recurred after treatment withdrawal in 2 of 11 in NA and 3 of 12 in MO group. That shows no significant difference between 2 groups (P > 0.05). Conclusion: We deduce that NA has the same efficacy and safety with MO and can induce a complete response in high percentage of the patients. Moreover, we observed no significant differences in the recurrence rate and outcomes after 3 months among the patients in both study groups; this result could support the use of NA in HRS management. The IRCT ID is: IRCT201107217085N1.http://www.ijpvmjournal.net/article.asp?issn=2008-7802;year=2012;volume=3;issue=11;spage=764;epage=769;aulast=TavakkoliClinical trialhepatorenal syndromemidodrinenoradrenalinoctreotide |
| spellingShingle | Hamid Tavakkoli Kambiz Yazdanpanah Marjan Mansourian Noradrenalin Versus the Combination of Midodrine and Octreotide in Patients with Hepatorenal Syndrome: Randomized Clinical Trial International Journal of Preventive Medicine Clinical trial hepatorenal syndrome midodrine noradrenalin octreotide |
| title | Noradrenalin Versus the Combination of Midodrine and Octreotide in Patients with Hepatorenal Syndrome: Randomized Clinical Trial |
| title_full | Noradrenalin Versus the Combination of Midodrine and Octreotide in Patients with Hepatorenal Syndrome: Randomized Clinical Trial |
| title_fullStr | Noradrenalin Versus the Combination of Midodrine and Octreotide in Patients with Hepatorenal Syndrome: Randomized Clinical Trial |
| title_full_unstemmed | Noradrenalin Versus the Combination of Midodrine and Octreotide in Patients with Hepatorenal Syndrome: Randomized Clinical Trial |
| title_short | Noradrenalin Versus the Combination of Midodrine and Octreotide in Patients with Hepatorenal Syndrome: Randomized Clinical Trial |
| title_sort | noradrenalin versus the combination of midodrine and octreotide in patients with hepatorenal syndrome randomized clinical trial |
| topic | Clinical trial hepatorenal syndrome midodrine noradrenalin octreotide |
| url | http://www.ijpvmjournal.net/article.asp?issn=2008-7802;year=2012;volume=3;issue=11;spage=764;epage=769;aulast=Tavakkoli |
| work_keys_str_mv | AT hamidtavakkoli noradrenalinversusthecombinationofmidodrineandoctreotideinpatientswithhepatorenalsyndromerandomizedclinicaltrial AT kambizyazdanpanah noradrenalinversusthecombinationofmidodrineandoctreotideinpatientswithhepatorenalsyndromerandomizedclinicaltrial AT marjanmansourian noradrenalinversusthecombinationofmidodrineandoctreotideinpatientswithhepatorenalsyndromerandomizedclinicaltrial |